SNPRC at Texas Biomed awarded $37 million NIH grant to continue operations into 2026
The Southwest National Primate Research Center (SNPRC) at Texas Biomedical Research Institute (Texas Biomed) has been awarded more than $37 million from the National Institutes of Health (NIH) to continue operations into 2026. The P51 grant, given by the NIH Office of Research Infrastructure Programs, provides essential funding to house and care for nearly 2,500 non-human primates that are part of life-science research programs at Texas Biomed and partners around the globe.
Non-human primates play an essential role in pre-clinical research, including most recently helping to show that the Pfizer-BioNTech COVID-19 vaccine would be safe and effective for humans, accelerating the clinical trials. The support from NIH for our Center will ensure that we can continue this critical work in finding new treatments and vaccines against a variety of infectious diseases, while maintaining the absolute highest
Press release content from Business Wire. The AP news staff was not involved in its creation.
New Study Presents Evidence of Effectiveness and Safety Of Oleandrin and Phoenix Biotechnology’s PBI-06150 Against SARS-CoV-2
March 17, 2021 GMT
An article published last week in the
Journal of Biomedicine & Pharmacotherapy ( www.elsevier.com/locate/biopha; Vol 138 (2021) 111457) presents
in vitro evidence for significant inhibition of SARS-CoV-2 by oleandrin and a defined extract of
N. oleander (developed by Phoenix Biotechnology, Inc. and designated as PBI-06150), as well as
in vivo evidence of the safety and efficacy of PBI-06150.
ADVERTISEMENT
The
Journal of Biomedicine & Pharmacotherapy is an open access, peer-reviewed medical journal covering medical applications of pharmacology. It was established in 1956 and is published 10 times a year.
New Study Presents Evidence of Effectiveness and Safety Of Oleandrin and Phoenix Biotechnology s PBI-06150 Against SARS-CoV-2 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
E-Mail
SAN ANTONIO (March 11, 2020) - Texas Biomedical Research Institute (Texas Biomed) received two Department of Defense s (DoD) Defense Health Agency subcontracts to assess the efficacy of surface coating and aerosolized decontamination technologies to combat SARS-CoV-2 and other respiratory pathogens on surfaces and in the air. The $4.6 million contracts, of which Texas Biomed will receive $1.95 million, are aimed at identifying viral and microbial decontamination strategies that improve indoor air quality and surfaces in medical treatment facilities, close quarters and rigorous settings where material cannot be disinfected regularly, as seen in many combat areas. Amber Mallory, Ph.D, Director of Trauma and Clinical Care Research for the 59th Medical Wing Science and Technology Office and Texas Biomed Professors Luis Martinez-Sobrido, Ph.D. and Jordi B. Torrelles, Ph.D are leading these efforts.
Macaques and baboons show success as models to study SARS-CoV-2
3
Researchers have shown rhesus macaques and baboons develop strong signs of acute viral infection from SARS-CoV-2, making them ideal models.
Scientists have published their findings regarding a comprehensive animal model that can be used to study SARS-CoV-2. The research was conducted at Texas Biomedical Research Institute (Texas Biomed) and Southwest National Primate Research Center (SNPRC), US.
The study evaluated three non-human primate (NHP) species (Indian rhesus macaques, African baboons and new-world origin common marmosets) and young and old animals, to determine susceptibility to the SARS-CoV-2 virus and the development of COVID-19 disease.